CRUK CI, credit Phil Mynott

Cancer Research UK Cambridge Institute

The Cancer Research UK Cambridge Institute aims to bring the scientific strengths of Cambridge to bear on practical questions of cancer diagnosis, treatment and prevention. The Institute focuses specifically on the practical application of high-quality basic research.

About us

Latest news

  • News

    Fanni Gergely elected to EMBO Membership

    Dr Fanni Gergely, Senior Group Leader at the Institute, has been elected as a member of the European Molecular Biology Organisation (EMBO) in recognition of her high quality life science research.  Fanni is one of 56 new members who are joining more than 1800 of the best researchers in Europe and around the world. Election to […]

    Find out more
  • News

    Dr Giulia Biffi joins Institute as new Group Leader

    We are delighted to announce that Dr Giulia Biffi is joining the Cancer Research UK Cambridge Institute as a new Group Leader in January 2020.  Dr Biffi studied at the University of Pavia in Italy for her Bacherlor’s and Master’s degrees before moving to Prof Sir Balasubramanian’s Group at the Cancer Research UK Cambridge Institute for […]

    Find out more
  • News

    Dr Stockis awarded Marie Curie Fellowship to investigate immune cell communication

    Dr Julie Stockis, Halim Group, has been awarded a prestigious Marie Skłodowska-Curie Fellowship to study how immune cells in the pancreas communicate with each other during pancreatitis and pancreatic tumour development. Although cancer survival has doubled over the last forty years, progress hasn’t been even across all cancer types. For pancreatic cancer, there has been […]

    Find out more
  • News

    Identifying active targets in hard to treat cancers

    Dr Geoff Macintyre and Dr Anna Piskorz have received a Cancer Research UK Innovation Prize to develop a test that could identify active therapeutic targets in hard to treat cancers. Over the last 40 years, improvements in prevention, detection and treatment have revolutionised cancer medicine and survival has doubled. However, progress has not advanced equally […]

    Find out more

Who we work with